AstraZeneca agreement with Quell Therapeutics
09 June 2023 AstraZeneca announces agreement with Quell Therapeuticsto develop, manufacture and commercialiseengineered T-regulatory cell therapies for autoimmune diseases Collaboration focused on Type 1 Diabetes and Inflammatory Bowel Diseaseusing Quell's proprietary multi-modular T-regulatory cell engineering AstraZeneca has entered into an exciting collaboration, exclusive option and license agreement with Quell Therapeutics to develop multiple engineered T-regulator (Treg) cell therapies that have the potential to be curative in Type 1 Diabetes (T1D) and Inflammatory